Enzolytics Inc (ENZC)

[Timing101]

OK , going into Second Week of November , can we get a TRIFECTA WEEK?
==
1. Completed Audit by Gries and Associates submitted. Charles indicated it in the PR and Gries Team represents many OTC symbols , they are all AUDITED except for their newest company which is ENZC.
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-Announces-Litigation-Success-Accounting-Progress-and-Removal-of-Yield-Sign-on-OTC-Markets-Stock-Quotes?id=372418
https://www.otcmarkets.com/learn/service-providers/9144?t=5
Note on this, Charles spent two almost three paragraphs in that PR speaking to it and how the Legal Item was successful, in other words things are not in the way and it will happen . Strong Statement, the question is since all are expecting it to happen in the near future (like next week) ,will it drive much volume as everyone knows about it . We will see .
--
2. Next, will ENZC become SEC Reporting , We know that Nov 14th is a key SEC Filing date on the SEC Calendar .That is coming up the Third week of November and one needs completed Financial and Audited statements to do so. We also Know that Gries and Associates do that and all their companies they represent (except one) are SEC REPORTING COMPANIES.
Note on this, if ENZC becomes SEC Reporting and files any updated 8-k news in the next few weeks , it will be a WHOLE DIFFERENT PICTURE and this will make ENZC into an Accountable SEC Symbol. This will drive VOLUME to a new level and folks will jump on to that. Read past the calendar here. https://www.gibsondunn.com/wp-content/uploads/2021/09/SEC-Filing-Deadline-Calendar-2022.pdf
--
3. Then on November 15th the next Disclosures are due and be prepared to some side by side reviews of Share Structure , updates through out . lets see if they come out on TIME , which is and would be a change with Gries and Associates being in charge now to the better.
https://www.otcmarkets.com/stock/ENZC/disclosure
Just coming on time would be a plus, but folks know it is coming and has to. So unless this came with an 8-k, not sure how much volume this would drive or at least a catalyst within the disclosure , such as the GLP study is completed and it came out positive.
Note on this , if there is indeed an 8-K filing event and disclosure news , beyond Audited Financials and SEC Reporting , expect a big push .
===
Ask yourself , It has been now over Two Years since Charles C and Team became the controlling parties assisting Harry Z move forward with Legal, Reincorporation, Tangent companies being developed, getting rid of toxic lenders , no increase in shares , plus documented Shares information (unheard of ) to the shareholders earlier this year. There truly is very little in the way now.
https://www.otcmarkets.com/otcapi/company/financial-report/323613/content
--
Then ReRead this about Charles Cotropia and his past experience level, make sure you go down and read about his 40+ years as a Corporate Partner in Legal and how many cases, how many patents and how many trademarks he has been involved with . I just re-read it again and said totally AMAZING..
Quote
"CEO of Enzolytics, Inc. CEO of Enzolytics, Inc.
Enzolytics, Inc. · Full-timeEnzolytics, Inc. · Full-time
Oct 2020 - Present · 2 yrs 2 mosOct 2020 - Present · 2 yrs 2 mos
Dallas-Fort Worth MetroplexDallas-Fort Worth Metroplex
Co-Founder and CEO / Board of DirectorsCo-Founder and CEO / Board of Directors
==
BioClonetics Immunotherapeutics, Inc.BioClonetics Immunotherapeutics, Inc.
Dec 2009 - Dec 2020 · 11 yrs 1 moDec 2009 - Dec 2020 · 11 yrs 1 mo
Dallas/Fort Worth AreaDallas/Fort Worth Area
BioClonetics Immunotherapeutics is a biotechnology company with a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. From this methodology, the company has created a proprietary cell line that produces a fully human monoclonal antibody that targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria.BioClonetics Immunotherapeutics is a biotechnology company with a proprietary methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. From this methodology, the company has created a proprietary cell line that produces a fully human monoclonal antibody that targets and neutralizes the HIV virus (i.e., renders the virus incapable of reproduction). The Company also has created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus and diphtheria.
==
MemberMember
American Bar AssociationAmerican Bar Association
1979 - 2016 · 37 yrs1979 - 2016 · 37 yrs
==
MemberMember
Dallas Bar AssociationDallas Bar Association
1973 - 2016 · 43 yrs1973 - 2016 · 43 yrs
Dallas, TexasDallas, Texas
===
Sidley Austin LLP logo
PartnerPartner
Sidley Austin LLPSidley Austin LLP
1996 - 2015 · 19 yrs1996 - 2015 · 19 yrs
Dallas, TexasDallas, Texas
As a partner with Sidley Austin LLP, Charles had over 19 years of litigation experience handling cases in Federal Court involving patents, trademarks, trade dress, unfair competition and copyrights. As an intellectual property attorney, he served as lead counsel in patent, trademark, trade dress and copyright disputes litigated in federal courts and the United States Patent and Trademark Office. Charles represented clients with products and services in many diverse areas, including automobile equipment, aerospace, electronics, the Internet, oil and gas equipment, wearing apparel and consumer products.
As a partner with Sidley Austin LLP, Charles had over 19 years of litigation experience handling cases in Federal Court involving patents, trademarks, trade dress, unfair competition and copyrights. As an intellectual property attorney, he served as lead counsel in patent, trademark, trade dress and copyright disputes litigated in federal courts and the United States Patent and Trademark Office. Charles represented clients with products and services in many diverse areas, including automobile equipment, aerospace, electronics, the Internet, oil and gas equipment, wearing apparel and consumer products.
==
PartnerPartner
Richards, Medlock & AndrewsRichards, Medlock & Andrews
Jun 1973 - Jul 1996 · 23 yrs 2 mosJun 1973 - Jul 1996 · 23 yrs 2 mos
Dallas, TexasDallas, Texas
As a partner with the law firm Richards, Medlock and Andrews, Charles had over 23 years of legal experience in the Intellectual Property field, handling litigation in the Patent and Trademark Office and in Federal and State Courts involving patents, trademarks, trade dress, unfair competition and copyrights. As an intellectual property attorney, he served as lead counsel in patent, trademark, trade dress and copyright disputes litigated in federal courts and the United States Patent and Trademark Office. Charles represented clients in numerous product and service fields and obtained for clients over 800 patents in the U.S. and foreign countries and registered over 1000 trademarks for his clients. "